{"id":"NCT00460265","sponsor":"Amgen","briefTitle":"Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer","officialTitle":"A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-05","primaryCompletion":"2010-05","completion":"2012-05","firstPosted":"2007-04-13","resultsPosted":"2011-06-14","lastUpdate":"2014-03-07"},"enrollment":658,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Recurrent and/or Metastatic Head and Neck Cancer"],"interventions":[{"type":"DRUG","name":"ARM 2","otherNames":[]},{"type":"DRUG","name":"ARM 1","otherNames":[]}],"arms":[{"label":"ARM 2","type":"ACTIVE_COMPARATOR"},{"label":"ARM 1","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the treatment effect of Panitumumab in combination with chemotherapy versus chemotherapy alone as first line therapy for metastatic and/or recurrent squamous cell carcinoma of the head and neck.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"Upto 56 months","effectByArm":[{"arm":"Panitumumab Plus Chemotherapy","deltaMin":11.1,"sd":null},{"arm":"Chemotherapy Alone","deltaMin":9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1403"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23746666"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":157,"n":325},"commonTop":["Nausea","Neutropenia","Vomiting","Anaemia","Diarrhoea"]}}